Thoughts on the Market

A Turnaround in Sight for Healthcare?

October 28, 2025
Listen, watch and subscribe:

A Turnaround in Sight for Healthcare?

October 28, 2025

Our U.S. Biotech and Biopharma analysts Sean Laaman and Terence Flynn discuss the latest developments that could be positioning the healthcare sector for strong outperformance.

Transcript

Sean Laaman: Welcome to Thoughts on the Market. I'm Sean Laaman, Morgan Stanley's U.S. Small and Mid-Cap Biotech Analyst.

 

Terence Flynn: And I'm Terence Flynn, Morgan Stanley's U.S. Biopharma Analyst.

 

Sean Laaman: Today, we'll discuss how a rally in the healthcare sector is being driven by more favorable macro conditions.

 

It's Tuesday, October 28th at 10am in New York.

 

So, Terence, healthcare has lagged the broader market year-to-date, and valuations have been near historical lows. But recent weeks show strengthening performance. Policy headwinds have been front and center.

What's changed in the regulatory environment and how is the biopharma sector adapting to these pricing and tariff dynamics?

 

Terence Flynn: Sean, as you know, with many other sectors, tariffs were initially a focus earlier this year. But a number of companies in our space have subsequently announced significant U.S. manufacturing investments to reshore supply chains. And hence, the market's less focused on tariffs in our space right now.

 

But the other policy dynamic and focus is what's called Most Favored Nation or MFN drug pricing. Now, this is where the President's been focused on aligning U.S. drug prices with those in other developed countries. And recently we've seen several companies announce agreements with the administration along these lines, which importantly has provided investors with more visibility here. And we're watching to see if additional agreements get announced.

 

Sean Laaman: Got it. Another hurdle for Large-cap biopharma is a looming expiration of patents with [$]177 billion exposed by 2030. How is this shaping M&A trends and strategic priorities?

 

Terence Flynn: For sure. I mean, as you know, Sean, patent expiry is our normal part of the life cycle of drug development. Every company goes through this at some point, but this does put the focus on company's internal pipelines to continue to progress while also being able to access external innovation via M&A. Recently we have started to see a pickup in deal activity, which could bode well for performance in SMID-cap biotech.

 

Sean Laaman: At the same time, you believe relative valuations look compelling for Large-cap biopharma. Where are valuations versus where they've been historically? What's driving this and how should investors think about positioning?

 

Terence Flynn: Absolutely. Look, on a price to earnings multiple, the sector's trading at about a 30 percent discount to the S&P 500 right now. Now that's in line with prior periods of policy uncertainty. But as policy visibility improves, we expect the focus will shift back to fundamentals. Now, positioning to me still feels light here, given some of the patent cliff dynamics we just discussed.

 

Now, Sean, with the Fed moving toward rate cuts, how do you see this impacting your sector on the biotech side?

 

Sean Laaman: Well, Terence, particularly in my space, which is Small- and Mid-cap biotech companies, they're typically capital consumers are not capital producers. They're particularly sensitive to the current rate environment.

Therefore, they're sensitive to spending on pipeline. They're sensitive to M&A. So, as rates come down, we expect more spending on pipeline and more M&A activity, which is generally positive for the sector. Looking forward, biotech sector is generally the best performing sector on a six-to-12-month timeframe post the first rate cut.

 

Terence Flynn: Great. You've also talked about this SMID to Big thesis on the biotech side. Can you explain what's driving that?

 

Sean Laaman: Sure Terence. There’s three pieces to the SMID to Big thematic. So, we in SMID-cap biotech, we cover 80 to 90 companies. About a third of those are newly, kind of profitable companies. Those companies are turning from being capital consumers to capital producers. We see about $15 billion of cash on balance sheets for 2025, going to north of 130 billion by 2030. That's the first piece.

 

The second piece is due to regulatory uncertainty at the USFDA. We're seeing more attractive valuations amongst clinical stage names. That's the second piece. And third piece relates to your coverage, Terence. I refer back to that [$]177 billion of LOE. So, we expect generally that M&A activity will be quite high amongst our sector.

 

Terence Flynn: And let's not forget about AI, which has implications across the healthcare space. How much is this changing the dynamic in biotech, Sean?

 

Sean Laaman: It is changing, but we're really at the beginning. I think there's three things to think about. The first one is faster trial recruitment. The second one is faster regulatory submissions. And the third one, which is the most interesting, but we're really at the beginning of, is faster time to appropriately targeted molecules.

 

Terence Flynn: Great. And maybe lastly, what are the key risks and catalysts for SMID-cap biotech in the current environment?

 

Sean Laaman: As always, we're focused on pipeline failures in terms of risk. Secondly, in terms of risk, we're looking at regulatory risk at the FDA. And thirdly, we're looking at the rise in China biotech and the competitive dynamic there.

Whether you're watching large cap biopharma, M&A moves, or the rise of cash-rich, SMID-cap biotechs, the healthcare sector setup is unlike anything we've seen in years.

Terence, thanks for speaking with me.

 

Terence Flynn: Always a pleasure to be on the show. Thanks for having me, Sean,

 

Sean Laaman: And thanks for listening. If you enjoy Thoughts on the Market, please leave us a review wherever you listen and share the podcast with a friend or colleague today.

 

Thoughts on the Market

Listen to our financial podcast, featuring perspectives from leaders within Morgan Stanley and their perspectives on the forces shaping markets today.

Up Next

Our U.S. Software Analyst Sanjit Singh explains how AI is reshaping software development and why t...

Transcript

Welcome to Thoughts on the Market. I’m Sanjit Singh, the U.S. Software Analyst at Morgan Stanley.

 

Today: how AI is transforming software and what that means for developers.

 

It’s Friday, October 24th, at 10am in New York.

 

There's been a lot of news stories and anecdotal accounts about AI taking over jobs, especially in the software industry. You may have heard of vibe coding, where people can use natural language prompts, guiding AI to build software applications. So yes, AI is creating a world where software writes itself. But at the same time, the demand for human creativity only grows.

 

The introduction of AI coding assistants has dramatically expanded what software can do, fueling a surge in both the volume of code and the complexity of projects. But instead of shrinking the developer workforce, AI is actually supporting continued growth in developer headcount, even as productivity soars.

 

We’re estimating the software development market will grow at a 20 percent compound annual growth rate, reaching $61 billion by 2029. And that’s up from $24 billion in 2024. And in terms of the developer population, [research] firms like IDC expect it to jump from 30 million paid developers in 2024 to 50 million by 2029 – that’s a 10 percent annual growth rate. Even the most conservative estimates, like those from the U.S. Bureau of Labor Statistics, see developer jobs growing roughly 2 percent per year through 2033, outpacing overall employment growth.

 

So, what does this mean for people behind the code? 

 

AI isn’t replacing developers. It’s redefining them. Routine tasks are increasingly handled by AI agents, and this frees up developers to become curators, reviewers, architects, and most important problem-solvers.

 

The upshot? Companies may need fewer developers for repetitive work, but the overall demand for skilled engineers remains robust. As AI lowers the barrier to entry, the pool of people who can build software applications expands dramatically. But at the same time, the complexity and ambitions of projects rise, keeping experienced developers in high demand.

 

No doubt, AI coding tools are delivering real productivity gains. Some teams are reporting nearly doubling their code capacity and cutting pull request times in half after adopting AI assistants. Test coverage has increased sharply, resulting in 20 percent fewer production incidents for some organizations. But there is a catch with all this AI-generated code. It’s creating significant new bottlenecks downstream.

 

An example of this is code review, which is becoming a major pain point. Many organizations are experiencing pull request fatigue, with developers rubber-stamping changes just to keep up. Some teams now require three reviewers for AI-generated change, compared to just one before. And in terms of automated testing, systems are getting overwhelmed because every change made with AI sets off a complete round of test.

 

Now we estimate productivity gains from AI in software engineering at about 15–20 percent. But in complex projects, the gains are much lower, as the volume of new code often means more bugs and more rework – and hence more human developers.

So where do we go from here? 

 

In our view, the future isn’t about fully autonomous software development. Instead, large enterprises are likely to favor an integrated approach, where AI agents and human developers work side by side. AI will automate more of the software development lifecycle. And that not only includes coding – which, coding typically accounts for 10-20 percent of the software development effort – but other areas like testing, security, and deployment. But humans will remain in the loop for oversight, design, and decision-making. And as software gets cheaper and faster to build, organizations won’t just do the same work with fewer people – they likely will do more.

 

In short, the need for skilled developers isn’t going away. But it’s definitely evolving. And in the age of AI, it’s not about man versus machine. It’s about man with machine. And so with more software, we see more developers.


Thanks for listening. If you enjoy the show, please leave us a review wherever you listen and share Thoughts on the Market with a friend or colleague today.

Morgan Stanley Thoughts on the Market Podcast
Our Head of Corporate Credit Andrew Sheets wades into the debate around whether the boom in artifi...

Transcript

Andrew Sheets: Welcome to Thoughts on the Market. I'm Andrew Sheets, Head of Corporate Credit Research at Morgan Stanley. 

 

Today – the debate about whether elevated capital expenditure and AI technology is showing classic warning signs of overbuilding and worries for credit.  

 

It's Thursday, October 23rd at 2pm in London. 

 

Two things are true. AI related investment will be one of the largest investment cycles of this generation. And there is a long history of major investment cycles causing major headaches to the credit market. From the railroads to electrification, to the internet to shale oil, there are a number of instances where heavy investment created credit weakness, even when the underlying technology was highly successful.  

 

So, let's dig into this and why we think this AI CapEx cycle actually has much further to run. 

First, Morgan Stanley has done a lot of good collaborative in-depth work on where the AI related spend is coming from and what's still in the pipeline. And importantly, most of the spending that we expect is still well ahead of us. It's only really ramping up starting now.  

 

Next, we think that AI is seen as the most important technology of the next decade by some of the biggest, most profitable companies on the planet. We think this increases their willingness to invest and stick with those investments, even if there's a lot of uncertainty around what the return on all of this expenditure will ultimately be.  

 

Third, unlike some other major recent capital expenditure cycles – be they the internet of the late 1990s or shale oil of the mid 2010s, both of which were challenging for credit – much of the spending that we're seeing today on AI is backed by companies with extremely strong balance sheets and significant additional debt capacity. That just wasn't the case with some of those other prior investment cycles and should help this one run for longer.  

 

And finally, if we think about really what went wrong with some of these prior capital expenditure cycles, it's often really about overcapacity. A new technology – be it the railroads or electricity or the internet – comes along and it is transformational. 

 

And because it's transformational, you build a lot of it. And then sometimes you build too much; you build ahead of the underlying demand. And that can lower returns on that investment and cause losses. 

 

We can understand why large levels of AI capital investment and the history of large investment cycles in the past causes understandable concern. But when tying these dynamics together, it's important to remember why large investment cycles have a checkered history. It's usually not about the technology not working per se, but rather a promising technology being built ahead of demand for it and resulting in excess capacity driving down returns in that investment, and the builders lacking the financial resources to bridge that gap. 

 

So far, that's not what we see. Data centers are still seeing strong underlying demand and are often backed by companies with exceptionally good resources. We need to watch if either of these change.  

 

But for now, we think the AI CapEx cycle has much further to go.  

 

Thank you as always for your time. If you find Thoughts on the Market useful, let us know by leaving a review wherever you listen. And also tell a friend or colleague about us today

Morgan Stanley Thoughts on the Market Podcast

More Insights